ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0468

Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes

Heejo Keum1, Bonnie Bermas2, Shivani Patel1, Benjamin Chong1 and Heidi Jacobe1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2UT Southwestern, Dallas, TX

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, pregnancy, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0460–0479) Reproductive Issues in Rheumatic Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and rheumatoid arthritis (RA). However, little is known about pregnancy outcomes in patients with autoimmune skin diseases (ASDs). We aimed to determine the frequency of APOs in patients with ASDs. We hypothesized that similar to rheumatic diseases, patients with ASDs would have a higher frequency of APOs than the general population.

Methods: This case-control study was conducted using the TriNetX US Collaborative Network, a database of electronic medical records of 94 million patients in the United States. Pregnant patients aged 15-44 years between January 1, 2016 and December 31, 2021 were included. Pregnancies were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) indicating pregnancy endpoints. Cases consisted of patients with at least one ASD diagnosed prior to the end of pregnancy. The ASDs identified were alopecia areata, bullous pemphigoid, cicatricial pemphigoid, dermatitis herpetiformis, cutaneous lupus erythematosus, epidermolysis bullosa acquisita, morphea, pemphigus foliaceus, pemphigus vulgaris, vitiligo, and amyopathic DM. There were 2 control groups: 1) healthy controls without ASDs, SLE, or RA and 2) disease controls defined as patients with SLE or RA. For all cases and controls, patients with hidradenitis suppurativa or other common autoimmune diseases such as Hashimoto’s thyroiditis and Type 1 diabetes were excluded. The primary outcomes were APOs defined as spontaneous abortion, gestational hypertension, preeclampsia/eclampsia, gestational diabetes, intrauterine growth restriction (IUGR), preterm premature rupture of membranes (PPROM), and preterm birth. Patients with ASDs and controls were 1:1 propensity score matched by age, race, ethnicity, comorbidities, obesity, and substance use. For each outcome, risk ratio (RR) with a 95% confidence interval (CI) was calculated.

Results: 3,654 patients with ASDs were matched to 3,654 healthy controls (Table 1). Patients with ASDs were more likely to have spontaneous abortions (RR=1.5 [1.4-1.7], P< 0.001), and preeclampsia/eclampsia (RR=1.2 [1.0-1.3], P=0.04) than healthy controls (Table 2). When compared to women with SLE, women with ASDs were less likely to have preeclampsia/eclampsia (RR=0.7 [0.6-0.9, p=0.001), have a preterm birth (RR= 0.5 [0.4-0.7], P< 0.001), PPROM (RR=0.6 [0.4-0.9], P=0.004), or an infant with IUGR (RR=0.6 [0.5-0.8], P< 0.001), and more likely to have a spontaneous abortion (RR=1.2 [1.1-1.3], P=0.003). Patients with ASDs had similar risks for APOs as patients with RA (Table 3).

Conclusion: These results suggest that patients with ASDs have increased rates of adverse pregnancy outcomes compared to healthy controls and are similar in risk to RA. In contrast, those with SLE have a greater frequency of APOs indicating that all these groups may benefit from multidisciplinary care with maternal-fetal medicine specialists. Further studies will be helpful to identify mechanisms behind increased risk of adverse pregnancy outcomes in patients with ASDs.

Supporting image 1

Table 1. Baseline characteristics of patients with ASDs, controls, and disease controls after propensity score matching

Supporting image 2

Table 2. Adverse pregnancy outcomes in patients with autoimmune skin diseases and controls after propensity score matching

Supporting image 3

Table 3. Adverse pregnancy outcomes in patients with autoimmune skin diseases and disease controls after propensity score matching


Disclosures: H. Keum: None; B. Bermas: None; S. Patel: None; B. Chong: Biogen Inc, 1, 2, 12, Site PI for Clinical Trial, Bristol-Myers Squibb(BMS), 2, EMD Serono, 2, Horizon Therapeutics, 2; H. Jacobe: None.

To cite this abstract in AMA style:

Keum H, Bermas B, Patel S, Chong B, Jacobe H. Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/patients-with-autoimmune-skin-diseases-are-at-increased-risk-of-adverse-pregnancy-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-autoimmune-skin-diseases-are-at-increased-risk-of-adverse-pregnancy-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology